Thrivent Financial for Lutherans Sells 102,124 Shares of Ingevity Corporation $NGVT

Thrivent Financial for Lutherans decreased its holdings in Ingevity Corporation (NYSE:NGVT) by 8.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,135,400 shares of the company’s stock after selling 102,124 shares during the period. Thrivent Financial for Lutherans’ holdings in Ingevity were worth $48,924,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Geneos Wealth Management Inc. increased its holdings in shares of Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after acquiring an additional 387 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Ingevity during the 2nd quarter worth $46,000. Elevation Point Wealth Partners LLC bought a new stake in Ingevity during the second quarter valued at about $60,000. BI Asset Management Fondsmaeglerselskab A S grew its stake in Ingevity by 21.6% in the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 1,670 shares of the company’s stock valued at $66,000 after purchasing an additional 297 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in Ingevity by 51.6% in the second quarter. EverSource Wealth Advisors LLC now owns 1,616 shares of the company’s stock valued at $70,000 after purchasing an additional 550 shares during the last quarter. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Ingevity Stock Down 2.2%

NYSE:NGVT opened at $57.59 on Tuesday. The company has a current ratio of 1.27, a quick ratio of 0.80 and a debt-to-equity ratio of 8.39. Ingevity Corporation has a twelve month low of $28.49 and a twelve month high of $61.77. The company has a market cap of $2.07 billion, a PE ratio of -31.64 and a beta of 1.40. The company’s 50 day moving average is $53.09 and its two-hundred day moving average is $50.96.

Ingevity (NYSE:NGVT) last posted its quarterly earnings results on Friday, March 24th. The company reported $0.78 earnings per share (EPS) for the quarter. Ingevity had a negative net margin of 5.14% and a positive return on equity of 103.69%. The business had revenue of $336.00 million during the quarter. Analysts anticipate that Ingevity Corporation will post 4.45 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Ingevity in a report on Wednesday, October 8th. BMO Capital Markets increased their target price on shares of Ingevity from $64.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Wall Street Zen lowered shares of Ingevity from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 6th. Finally, Wells Fargo & Company upped their price target on Ingevity from $52.00 to $55.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 12th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $62.50.

Ingevity Company Profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.